{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-030940","form_type":"8-K","ticker":"BCDA","cik":"0000925741","company_name":"BioCardia, Inc.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.433595+00:00","generated_at":"2026-06-08T12:45:00.750642+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioCardia Q3 net loss narrows to $2.6M; CardiAMP HF trial paused after DSMB review","bullets":["Q3 2023 revenue $357K (up 68% YoY); net loss $2.6M improves from $3.1M YoY.","DSMB recommended pause of CardiAMP HF trial; management agrees primary endpoint unlikely with current design.","Subset analysis: NT-proBNP>500 patients showed 59% relative risk reduction in mortality (p=0.028).","Company submitted new protocol (CardiAMP HF II) to FDA targeting responders; Japan PMDA consultation set for Nov 21.","Cash used in operations $2.4M; anticipates two Helix licensing/development partnerships in Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-030940","json":"https://secwatch.observer/filing/0001437749-23-030940.json","markdown":"https://secwatch.observer/filing/0001437749-23-030940.md","text":"https://secwatch.observer/filing/0001437749-23-030940.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/925741/000143774923030940/0001437749-23-030940-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/925741/000143774923030940/bcda20231107_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T12:45:00.750642+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"54549d5ba66a14fe4f09b3b9f63dc3187d371a2d","claim":"BioCardia, Inc. reported financial results for the quarter ended September 30, 2023.","evidence_excerpt":"On November 8, 2023, BioCardia, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/925741/000143774923030940/0001437749-23-030940-index.htm","confidence":0.89,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}